Kindstar Global (Beijing) Technology, Inc. is a Chinese enterprise that specializes in providing advanced clinical testing services, including esoteric diagnostic and laboratory testing, to hospitals across the country, particularly tertiary care facilities. Founded in 2003 and based in Wuhan, the company operates laboratory facilities in key cities such as Beijing, Shanghai, and Wuhan. Kindstar Global is committed to enhancing personalized medicine and specialized clinical services by developing innovative testing technologies and methods. In addition to diagnostic services, the company offers medical research, clinical trial services, and translational medicine studies, catering to the needs of physicians, medical institutions, and pharmaceutical companies. The organization adheres to international standards and guidelines to prioritize patient interests and healthcare provider requirements.
Haixi Biotechnology is a research and development company of medical testing reagents, aiming to provide accurate testing reagents for medical special inspections, and provide complete scientific research reagents and services for biomedical researchers. Haixi is committed to the R&D, production, sales and service of medical diagnostics and biomedical research reagent products.
NeoImmune
Seed Round in 2021
NeoImmune is a technology developer focused on advancing the understanding and treatment of the immune system, particularly through the development of reagents for minimal residual disease (MRD) testing. The company specializes in high-throughput techniques for reading and writing T and B lymphocyte receptor profiles, which are essential for enhancing disease detection and clinical applications. Recently, NeoImmune completed a significant financing round to support the promotion of its MRD products and the research and development of new clinical innovations. The funding was led by Kangsheng Global, with participation from several notable investors, reaffirming NeoImmune's commitment to improving outcomes in hematological tumors and other diseases through cutting-edge immune system research.
Tailai Biosciences
Seed Round in 2020
TaiLai Biosciences is a biotechnology company based in Shanghai, China, focused on advancing cancer research through its proprietary multiomics technology. The company specializes in developing non-invasive cancer screening and analysis methods, which facilitate a deeper understanding of cancer development and aid in the creation of immune-guided therapies. TaiLai Biosciences offers a range of biopsy products and services that leverage extensive biological data, including DNA, RNA, proteins, and metabolic small molecules. By utilizing bioinformatics and computational science, the company aims to uncover correlations within this complex biological information, ultimately enhancing the effectiveness of cancer diagnosis and treatment.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.